August 6, 2025 7:48am

Always consider it, a glass half-full as Q2 earnings season results have mostly net losses, with 4 net incomes of 14 releases so far

Earnings <last night – Tuesday>: Supernus Pharmaceuticals (SUPN) <Acquired SAGE), Ultragenyx Pharmaceuticals (RARE)<see The Bottom Line>

Earnings today: Sarepta Therapeutics (SRPT)

Pre-open Signals: 2 Positive Indications after weak aftermarket

On point, short on words, long on informing facts and being judicious!

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

There are buying opportunities and sell signals, but many names are likely to reverse direction after the open, especially following earnings.

My “posts” are conveyed with a simplicity of language to highlight what is informative.

 

Tuesday’s night’s … RegMed Investors (RMi) Closing Bell: Whoa … https://www.regmedinvestors.com/articles/14049

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The pre-open Dow futures are UP +0.35% or (+155 points), the S&P futures are UP +0.23% or (+14 points) and the Nasdaq futures are UP +0.22% or (+50 point)

  • Stock futures rose Wednesday, 8/6
  • European markets floated mixed after Trump threatens 250% tariffs,
  • Asia-Pacific markets traded mixed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed DOWN -61.90 points or -0.14%, the S&P closed DOWN -30.77 points or -0.49% while the Nasdaq closed DOWN -137.03 points or -0.65%
  • Monday: The Dow closed UP +585.06 points or +1.34%, the S&P closed UP +91.93 points or +1.47% while the Nasdaq closed UP +403.45 points or +1.95%
  • The past week, the Dow tumbled -2.9% <its worst week since April 4>, the S&P 500 dropped -2.4% <for its worst weekly performance since May 23> and the Nasdaq lost -2.2

Economic Data Docket: none with 2 Fed president speeches

 

Q3 – August - 2 negative and 1 positive closes

  • July – 1 market holiday, 13 positive and 9 negative closes

 

Coverage Dropped: bluebird bio (BLUE) Private Equity acquired, Blueprint Medicine (BPMC) acquired by SNY, Homology Medicine (FIXX), Sage Therapeutics (SAGE) acquired by SUPN, Verve Therapeutics (VERV) – acquired by LLY

Added: BioNTech (BNTX), Sarepta Therapeutics (SRPT), Supernus Pharma (SUPN), IQVIA Holdings (IQV) and Wave Life Sciences Ltd. (WVE)

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I’ll pass; …. an escape in the making of more earnings releases, upcoming econs <Thursday>, ups, downs and just plain uncertainty

Although:

Supernus Pharma (SUPN) closed up +$0.48 post earnings release after Monday’s +$1.54 with a positive +$1.58 or +4.21% pre-open indication

CRISPR Therapeutics (CRSP) closed down -$4.00 after Monday’s +$3.50, Friday’s -$0.17, Thursday’s -$1.42, last Wednesday’s -$1.34, and the previous Tuesday’s -$4.73 Monday’s -$1.01 with a positive +$0.64 or +1.15% pre-open 

 

The BOTTOM LINE: Dow futures were “floating” higher …

  • After Tuesday declared losses after the ISM services index <edged down to 50.1 with the employment subindex further below the break-even 50 level and price pressures continuing to build> had a stagflation vibe.

Questionable Decision:

The Department of Health and Human Services said it is winding down its mRNA vaccine-development activities under the Biomedical Advanced Research and Development Authority.

  • The move includes terminating 22 vaccine investments and canceling and shrinking various contracts and solicitations
  • Moderna (MRNA) should feel the pain; along with Pfizer (PFE), and Sanofi (SNY) as traders reacted to the U.S. government’s move to halt future mRNA vaccine development under the Biomedical Advanced Research and Development Authority (BARDA). Retail sentiment also soured on AstraZeneca (AZN) after its vaccine partnership was identified as part of the federal wind-down.

 

August begins as July ends: understand the “flow” …

  • 8/5 – Tuesday closed negative with 15 positive, 19 negative and 1 flat
  • 8/4 – Monday closed positive with 27 positive, 8 negative and 0 flats
  • 8/1 – Friday closed negative with 9 positive, 20 negative and 6 flats

Last Week:

  • 7/31 - Thursday closed negative with 3 positive, 25 negative and 7 flats
  • 7/30 - Wednesday closed negative with 12 positive, 18 negative and 5 flats
  • 7/29 – Tuesday closed negative with 8 positive, 22 negative and 5 flats
  • 7/28 – Monday closed negative with 14 positive, 16 negative and 5 flats

 

Earnings are the highlight of the week:

8/7 Thursday = Intellia Therapeutics (NTLA), Regenxbio (RGNX) and 8/11, Monday = Agenus (AGEN)

  • Meeting earnings expectation and/or missing consensus will deem share pricing outcomes this week.

 

Earnings to date:

  • Supernus Pharma (SUPN) a net income of +$22.5M or +$0.40 per share with revenue of $165.5 M and a cash position of $522.6 and a runway beyond 2028
  • Ultragenyx Pharmaceuticals (RARE) a net loss of -$114.9 M or -$1.17 per share, revenue of $166.5 M, a cash position of $339 M with a runway until 2027
  • Beam Therapeutics (BEAM) a net loss of -$102.3M or -$1.00 per share with revenue of $8.7 M and a cash position of $1.2 B and a runway beyond 2028
  • AxoGen (AXGN) a net income of +$579 K or +0.01 per share, revenue of $56.7 M, a cash position of $35.9 M with a runway until 2026
  • Cellectis SA (CLLS) a net loss of -$18.1 M or -$0.24 per share, revenue of $30.2 M, a cash position of $230 M and a runway until 2H/27.
  •  CRISPR Therapeutics (CRSP) a net loss of -$208.5 M or -$2.40 per share, revenue of $45.2 M, a cash position of $1.7 B and a N/A runway
  • Moderna (MRNA) a net loss of -$0.8 B, or -$2.13 per share with revenue of $142 M, an R&D and an SG&A decrease and a cash position of $7.5 B with a runway until 2026 <beats revenue estimate and earnings consensus>.
  • Sage Therapeutics (SAGE): net loss of -$49.7 M or -$0.79 per share, revenue of $23.2M, a cash position of $366 M – acquired
  • Vericel (VCEL): net loss of -$0.06 M or -$0.01 per share, revenue of $63.2M, a cash position of $164 M and a runway until 2027
  • Alnylam Pharmaceuticals (ALNY): net loss of -$66.3 M or -$0.51 per share, revenue of $773.7 M, a cash position of $2.86 B and a N/A runway
  • Lenz Therapeutics (LENZ): net loss of -$14.9 M or -$0.53 per share, revenue of $5 M, a cash position of $209.6 M and a runway until 2026
  • uniQure NV (QURE): a net loss of -$37.7 M, or -$0.69 per share with revenue of $5.3 M, an R&D increase and an SG&A decrease and a cash position of $377.7 M with a runway until 2H/27 <missed revenue estimate and consensus>
  • Ionis Pharmaceuticals (IONS): a net income of +124 M, or +$0.70 per share with revenue of $452 M, and a cash position of $2.3 B with a runway until FY28 < estimate and consensus beats>
  • MiMedx (MDXG): a net income of +$100 M or +$0.06 per share with revenue of $99 M and a cash position of $100 M with a runway until 2026.

 

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • As always, I brace myself for earnings associated with share pricing volatility, some economics and tariff developments and their effects?

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.